The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida

Current Infectious Disease Reports

Volumn 8, Issue 6, 2006, Pages 442-448

  Patterson, Thomas F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLODEXTRIN; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; FUSARIUM; HUMAN; LIVER DYSFUNCTION; LIVER TOXICITY; MYCOSIS; NAUSEA AND VOMITING; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PRACTICE GUIDELINE; REVIEW; SALVAGE THERAPY; SCEDOSPORIUM APIOSPERMUM; SKIN TOXICITY; VISUAL DISORDER; ZYGOMYCETES;

EID: 33750872294     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0018-4     Document Type: Review

References (65)

1. McNeil MM, Nash SL, Haijeh RA, et al.: Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001, 33:641-647.
2. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001, 32:358-366.
3. Patterson TF, Kirkpatrick WR, White M, et al.: Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine (Baltimore) 2000, 79:250-260.
4. Chamilos G, Luna M, Lewis RE, et al.: Invasive fungal infections (lFIs) in patients (pts) with hematological malignancies (1989-2003): an autopsy study [abstract M-720]. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 16-19,2005.
5. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH: Amphotericin B: time for a new "gold standard." Clin Infect Dis 2003, 37:415-425.
6. Patterson TF, Boucher HW, Herbrecht R, et al.: Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005, 41:1448-1452.
7. Patterson TF: Advances and challenges in management of invasive mycoses. Lancet 2005, 366:1013-1025.
8. Dodds Ashley ES, Lewis R, Lewis JS, et al.: Pharmacology of systemic antifungal agents. Clin Infect Dis 2006, 43:S29-39.
9. Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004, 64:1997-2020.
10. Andes D: Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 2004, 17:533-540.
11. Denning DW: Echinocandin antifungal drugs. Lancet 2003, 362:1142-1151.
12. Wingard JR, Kubilis P, Lee L, et al.: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999, 29:1402-1407.
13. Bowden R, Chandrasekar P, White MH, et al.: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002, 35:359-366.
14. Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
15. Sutton DA, Fothergill AW, Rinaldi MG: Aspergillus in vitro antifungal susceptibility data: new millennium trends [abstract 16]. Presented at the Abstracts of Advances Against Aspergillosis. San Francisco, CA; September 9-11, 2004.
16. Walsh TJ, Goodman JL, Pappas P, et al.: Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob Agents Chemother 2001, 45:3487-3496.
17. Walsh TJ, Teppler H, Donowitz GR, et al.: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351:1391-1402.
18. Linden PK, Coley K, Fontes P, et al.: Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin Infect Dis 2003, 37:17-25.
19. Barrett JP, Vardulaki KA, Conlon C, et al.: A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003, 25:1295-1320.
20. Cornely OA, Maertens J, Bresnik M, Herbrecht R: Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): A randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial) [abstract]. Blood 2005, 106:3222.
21. Bowman JC, Hicks PS, Kurtz MB, et al.: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002, 46:3001-3012.
22. Maertens J, Raad I, Petrikkos G, et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563-1571.
23. Perea S, Gonzalez G, Fothergill AW, et al.: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002, 46:3039-3041.
24. Petraitis V, Petraitiene R, Sarafandi AA, et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003, 187:1834-1843.
25. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF: Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564-2568.
26. Marr KA, Boeckh M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802.
27. Marr KA, Crippa F, Leisenring W, et al.: Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004, 103:1527-1533.
28. Pfaller MA, Messer SA, Hollis RJ, Jones RN: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002, 46:1032-1037.
29. Steinbach WJ, Stevens DA: Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003, 37(Suppl 3):S157-187.
30. Denning DW, Ribaud P, Milpied N, et al.: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563-571.
31. Schwartz S, Ruhnke M, Ribaud P, et al.: Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005, 106:2641-2645.
32. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al.: Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004, 39:192-198.
33. Jorgensen KJ, Gotzsche PC, Johansen HK: Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006:CD004707.
34. Jorgensen KJ, Johansen HK, Gotzsche PC: Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. Trials 2006, 7:3.
35. Smith J, Safdar N, Knasinski V, et al.: Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006, 50:1570-1572.
36. Raad I, Chapman S, Bradsher R, et al.: Posaconazole (POS) salvage therapy for invasive fungal infections (IFI) [abstract M-699]. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 30-November 2, 2004.
37. Ullmann AJ, Lipton JH, Vesole DH, et al.: Posaconazole (POS) vs fluconazole (FLU) for prophylaxis of invasive fungal infections (IFIs) in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host-disease (GVHD): Results of a multicenter trial [abstract M-716]. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 16-19, 2005.
38. Cornely OA, Maertens J, Winston DJ, et al.: Posaconazole (POS) vs standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): Impact on mortality [abstract M-722b]. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 16-19, 2005.
39. Ullmann AJ, Cornely OA, Burchardt A, et al.: Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006, 50:658-666.
40. Raad II, Graybill JR, Bustamante AB, et al.: Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006, 42:1726-1734.
41. Kontoyiannis DP, Lionakis MS, Lewis RE, et al.: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1359.
42. Marr KA, Carter RA, Crippa F, et al.: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917.
43. Pappas PG, Alexander B, Marr K, et al.: Invasive fungal infections (IFIs) in hematopoietic stem cell (HSCTs) and organ transplant (OTRs): Overview of the TRANSNET database [abstract 671]. Presented at the 42nd Annual Meeting of the Infectious Diseases Society of America. Boston, MA; September 29-October 4, 2004.
44. Perfect JR: Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005, 40(Suppl 6):S401-408.
45. Greenberg RN, Mullane K, van Burik JA, et al.: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
46. van Burik JA, Hare RS, Solomon HF, et al.: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-65.
47. Ibrahim AS, Bowman JC, Avanessian V, et al.: Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005, 49:721-727.
48. Perfect JR, Marr KA, Walsh TJ, et al.: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122-1131.
49. Raad, II, Hachem RY, Herbrecht R, et al.: Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006, 42:1398-1403.
50. Revankar SG, Sutton DA, Rinaldi MG: Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004, 38:206-216.
51. Pappas PG, Rex JH, Lee J, et al.: A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643.
52. Pappas PG, Rex JH, Sobel JD, et al.: Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-189.
53. Marr KA, Seidel K, White TC, Bowden RA: Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infec Dis 2000, 181:309-316.
54. Uzun O, Anaissie EJ: Antifungal prophylaxis in patients with hematological malignancies: A reappraisal. Blood 1995, 86:2063-2072.
55. Mora-Duarte J, Betts R, Rotstein C, et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029.
56. Ruhnke M, Kuse E, Chetchotisakd P, et al.: Comparison of micafungin and liposomal amphotericin B for invasive candidiasis [abstract M-722c]. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 16-19,2005.
57. Reboli A, Rotstein C, Pappas P, et al.: Anidulafungin vs fluconazole for treatment of candidemia and invasive candidiasis (C/IC) [abstract M-7181]. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; December 16-19, 2005.
58. Marr KA, Hachem R, Papanicolaou G, et al.: Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004, 6:110-116.
59. Vazquez JA: Anidulafungin: A new echinocandin with a novel profile. Clin Ther 2005, 27:657-673.
60. Pfaller MA, Messer SA, Boyken L, et al.: In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004, 48:201-205.
61. Pfaller MA, Messer SA, Boyken L, et al.: Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol 2004, 42:3137-3141.
62. Kullberg BJ, Sobel JD, Ruhnke M, et al.: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442.
63. Bates DW, Su L, Yu DT, et al.: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001, 32:686-693.
64. Wingard JR, White MH, Anaissie E, et al.: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000, 31:1155-1163.
65. Leenders ACAP, Daenen S, Jansen RLH, et al.: Liposomal amphotericin B compared with amphotericin B deoxy-cholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Brit J Haematol 1998, 103:205-212.